Transcatheter valve prosthesis for blood vessels
阅读说明:本技术 用于血管的经导管瓣膜假体 (Transcatheter valve prosthesis for blood vessels ) 是由 E·帕斯奎诺 F·博内蒂 F·奥斯塔 S·奥斯塔 于 2018-04-23 设计创作,主要内容包括:一种用于血管的经导管临时瓣膜假体,该经导管临时瓣膜假体包括可扩张支撑结构(5”)、瓣膜(7)、过滤器(12)以及输送器(6);所述支撑结构(5”)在扩张时形成管状形状,具有远端和近端,所述瓣膜(7)位于所述远端处,并且所述输送器(6)从所述近端向所述远端在所述支撑结构(5)内延伸,并且包括适于充当用于其他装置的引入器的中心通道。(A transcatheter temporary valve prosthesis for a blood vessel, the transcatheter temporary valve prosthesis comprising an expandable support structure (5 "), a valve (7), a filter (12), and a conveyor (6); the support structure (5 ") forms a tubular shape when expanded, having a distal end at which the valve (7) is located and a proximal end, and the transporter (6) extends within the support structure (5) from the proximal end to the distal end, and comprises a central channel adapted to act as an introducer for other devices.)
1. A transcatheter temporary valve prosthesis for a blood vessel, the transcatheter temporary valve prosthesis comprising an expandable support structure (5 "), a valve (7), a filter (12), and a conveyor (6); the support structure (5 ") forms a tubular shape when expanded, having a distal end at which the valve (7) is located and a proximal end, and the transporter (6) extends within the support structure (5) from the proximal end to the distal end, and comprises a central channel adapted to act as an introducer for other devices.
2. The prosthesis according to claim 1, wherein the filter (12) and the conveyor (6) are combined in such a way as to form a single element.
3. The prosthesis according to claim 1, wherein the filter (12) is positioned against an inner wall of the support structure (5).
4. The prosthesis of any one of the preceding claims, wherein the carrier comprises a funnel portion on the proximal end and a tubular portion on the distal end.
5. The prosthesis of claim 4, wherein: the distal end of the conveyor (6) comprises a two-way normally closed valve that can be passed through as required to act as a leak-free introducer for other devices (6 ").
6. Prosthesis according to any of the previous claims, wherein the valve (7) comprises several leaflets.
7. Prosthesis according to any of the preceding claims, adapted to be deployed and positioned in an anatomical operation site, having the function of supporting the blood circulation in case of acute significant valve insufficiency.
8. The prosthesis according to claim 7, adapted to have the function of supporting blood circulation in case of acute pronounced aortic valve insufficiency.
9. The prosthesis according to claim 8, comprising a periaortic vessel deflector (9) adapted to be placed along the periaortic vessels, which prevents embolisation of debris into them.
10. Prosthesis according to claim 8 or 9, comprising two coronary deflectors (8) adapted to be placed in front of the coronary ostia, preventing debris emboli into the coronary arteries.
11. Prosthesis according to any of the previous claims, wherein said valve (7), said filter (12) and said conveyor (6) are located inside said supporting structure (5 ").
12. Prosthesis according to any of the previous claims, wherein the support structure (5 ") has a tapered end comprising a plurality of captive struts (4 ', 4") adapted to engage an internal conduit (3 '), wherein the structure is collapsible from an expanded state to a compressed state by pulling on the captive struts (4 ', 4 ").
Technical Field
The present invention relates to expandable prosthetic valves designed to be positioned within a vessel during repair or replacement of a native valve, such as an aortic valve.
Background
The clinical complications associated with transcatheter heart valve prosthesis (TAVI) implantation are mainly related to the fact that it overlaps with the diseased native valve. The severe presence of tissue calcification involving the valve device and surrounding tissue affects the proper deployment of the prosthesis, which allows for the onset of embolism.
Thus, the different types of clinical complications associated with TAVI implantation are mainly related to dystrophic calcification of the native valve and heterogeneous deployment of the valvular prosthesis, and are:
moderate to severe perivalvular leaks (grade II)
Occurrence of embolic events (blood clots and fibers or calcified emboli)
The incidence of moderate to severe perivalvular leakage (PVL) after transcatheter aortic valve prosthesis implantation was at least 10%, with mortality peaks around one year for this particular subgroup of patients.
For PVL, the clinical data applicable to the second generation transcatheter heart valves is vastly superior to the first generation clinical data. In fact, the incidence of moderate PVL dropped to 3.4%, but different authors recorded a higher percentage of PVL complications in patients with "high calcium scoring valves".
Coronary occlusion is a clinical complication arising from two different causes, namely mechanical occlusion of the coronary ostia caused by native leaflets of the aortic valve or embolization of calcium debris during TAVI implantation surgery. Although the incidence of this clinical complication is only 1% of TAVI implantation, it is fatal in 50% of cases even with a delay of several days after implantation surgery. The spread of TAVI implantation to intermediate risk patients further increases the severity of events to a younger patient population.
Mechanical occlusion of the coronary ostia may occur because TAVI pushes calcified native leaflets outward during its deployment, which creates an occlusion of the coronary ostia. The same may occur when TAVT is implanted on a degenerated bioprosthesis. Particularly with respect to certain bioprostheses, such as "stentless" bioprostheses, risky coronary ostia occlusion is more frequent when TAVI is implanted.
Surgical embolic events (so-called "macroembolic brain events") occur during TAVI implantation surgery (before, after or after dilation) and are mainly associated with the embolization of macroscopic fragments of calcium that are usually targeted to fibroelastic particles of the brain (stroke), coronary arteries or surrounding organs. However, stroke is the most feared clinical event, with a 2.7% incidence present and a 3.3% incidence of TAVI of the previous generation. The reduction in stroke is associated with a smaller need before and after dilation during TAVI implantation, but the data is unclear as it relates to aortic valves that are slightly calcified.
Post-operative microembolism brain events were recorded in at least 8% of patients under investigation. The high incidence of new brain injury following TAVI requires long-term assessment of neurocognitive function.
In this study, performed during a short follow-up period of 3 months, no neurocognitive function impairment was clinically observed, and most of the impairment (80%) had resolved on the 3-month MRI. However, once the indication of TAVI expands to include younger patients with long life expectancy, perioperative cerebral embolism problems and their potential impact on neurocognitive function may be predictive of greater clinical significance. Thus, future research in the TAVI field should be devoted to developing strategies to reduce the risk of embolism (e.g. less trauma, smaller-bore catheter systems, improved identification of patients at risk of embolism and possible use of brain protection devices).
In some clinical studies, at least 10% of patients receiving TAVI implants showed detectable nerve damage during cardiac intellectual testing. While this incidence is acceptable in high risk and elderly patients, it does not appear to be acceptable in younger patients at lower risk. Several clinical studies are being conducted to better investigate this clinical situation.
Another embolic event is sub-acute and chronic microembolic events that occur immediately after surgery. The native aortic calcified valve is rough with a warty surface that behaves like an atherosclerotic ulcer plaque after fixation. This condition favors the formation of microthrombosis, which later cause embolisms towards the brain and other surrounding organs. Native aortic valves left in place as a source of microemboli are considered in several clinical studies that suggest their role in the onset of angiogenic dementia. This evidence is alarming when TAVI is implanted in younger patients, in which case acceleration of vascular dementia may severely impact social costs.
In summary, perioperative clinical complications following TAVI implantation are strongly associated with the presence of heavily calcified aortic valves left in situ. Acutely, it causes macroembolic brain events (stroke) and the occurrence of hemodynamic consequences (e.g. PVL), which lead to various severe aortic insufficiency. These unsatisfactory clinical results are closely related to the irregular deployment of transcatheter valve prostheses with highly calcified native aortic valves.
A longer-term clinical complication is characterized by cerebral microembolism, which results from the leaflets of the aortic valve remaining in place, which are the source of emboli leading to vascular dementia.
The total clinical complication rate for TAVI is between 5% and 12%. This incidence is likely to be underestimated because it does not include patients with highly calcified and mitral native valves.
These evidence highlights the importance of protecting the surrounding organs (especially the brain and heart) from emboli that occur during TTWI surgery.
Today, there are several devices on the market that protect organs from embolic products, acting as deflectors or anti-embolic filters. In the case of the deflector, the protection system deflects the emboli from the brachiocephalic trunk and left common carotid artery towards the peripheral circulation. In the case of anti-emboli filters, they actually trap emboli with a net.
International patent application WO 2015/185870 discloses a temporary valve prosthesis designed to be inserted into the aortic root at the sinotubular junction.
The device includes a filter housed within a valve having a conical shape.
The above-referenced arrangement provides some improvements over other prior art arrangements. However, it presents some inconveniences, such as the risk of leakage caused by blood reflux or by difficulties in inserting additional devices through the prosthesis due to catheter size limitations.
Disclosure of Invention
The inconveniences discussed in the previous sections are solved by means of the present invention, which relates to a device as defined in the claims.
More specifically, the present invention includes an integrated system that simultaneously provides anti-emboli protection, valve function, and a self-centering transporter for other devices. The transporter function is adapted to enter and center a transcatheter device (a device for reducing native leaflet stiffness or partial/complete ablation of a native valve) or TAVI or other valve to be implanted operating on a diseased native valve. Thus, the system may optimize the entire TAVI procedure and may be very effective in reducing acute perioperative clinical complications that may occur, particularly in complex procedures.
The device according to the invention is conceived to be completely collapsed inside a catheter and introduced into the artery of a patient, intended to reach the aortic arch and to be deployed in position. The device allows for the passage of a different transcatheter device than that used to perform surgery on the native valve, while providing temporary valve support and protecting the heart, brain, and surrounding organs from any kind of embolism.
The device may be fully or partially collapsed for repositioning during surgery. At the end of the procedure, the device is collapsed, retracted within the shaft and completely removed from the patient.
The device preferably has a valve prosthesis housed within a shaped support structure that is leak-free coupled to the aortic wall. The second structure, either internal or distal with respect to the support structure, acts as an anti-embolus filter. A third structure, referred to as a delivery device, having a tapered or funnel-like shape, may be internal or distal with respect to the support structure and pass through the inner lumen of the valve prosthesis. It has the function of creating a catheter across the device and facilitating the introduction of several transcatheter devices operating on the diseased aortic valve and the relative alignment with respect to the valve axis.
In one embodiment, the valve prosthesis is anchored to an inner surface of the support structure. In this case, the expansion of the outer support structure in contact with the aortic wall is accommodated by the inner valve prosthesis. Therefore, the device must be accurately dimensioned at the time of intervention in order to avoid prosthetic valve insufficiency with limited efficacy in terms of hemodynamic performance and anti-embolic protection.
In another set of embodiments, the valve prosthesis can be considered independent of the embolic filter, so that the expansion of the latter fits to the aortic wall without interfering with the function of the valve prosthesis. This embodiment requires that the external support structure and the internal valve prosthesis are connected by some sort of septum. Thus, the size of the inner valve prosthesis, when fitted to the aortic wall, varies independently of the diameter of the outer support structure. Several embodiments belong to this group, differing in the positioning of the filter and the conveyor element and in the material of the support structure, i.e. embodiments with the conveyor and/or the filter inside or outside the main support structure and embodiments in which all support structures are made of self-expanding metallic material or expandable structures or a mixture thereof.
Detailed description of the invention
The invention will be better understood in relation to some illustrative examples.
Reference numerals used in the drawings
1 guide wire
2 balloon catheter tip
3 external shaft catheter of device
Internal shaft catheter for 3' device
4 device
4 'captive strut connecting the device to inner core catheter 3'
4 "captive
5 external support structure of device
5' anchoring holes to the filter screen
5 "Combined internal Structure (comprising
5' "captive strut having a locking hole connecting the
6 conveyor (integrated in 4 or external)
Inner lumen of 6' conveyor
6' distal conveyor tube with two-way normally closed valve
6 "' anchoring hole for a conveyor placed outside the
7 leaflet of an endoprosthesis
8 coronary artery deflector
9 periaortic (endovascular) vessel deflector
10 nets mounted on the inner or outer surface of the
11 to the inner shaft guide 3' (connection ring)
11' connecting ring, which connects the device with the
12 anti-bolt filter screen, normally mounted on the
13 connecting diaphragm between external support structure and internal valve prosthesis structure 12
14 valve support stent
14' leaflet anchoring structure
14 connecting strut between
15 prosthetic valve
16 an inflatable structure
17 mechanism for forcing the
18 radiopaque marker
Drawings
FIG. 1: a
FIG. 2: a
FIG. 3: a
FIG. 3 a: the
FIG. 4: a
FIG. 4 a: the
FIG. 5: the mixing
FIG. 6: the mixing
FIG. 7: a
FIG. 7 a:
FIG. 7 b:
FIG. 7 c:
FIG. 7 d:
FIG. 7 e:
FIG. 8: an
FIG. 9: an
FIG. 9 a: an
FIG. 9 b: the combined
FIG. 10 a: the internal structure of the
FIG. 10 b: different views of fig. 10.
FIG. 11:
FIG. 12: a
FIG. 13: as shown in fig. 12, an apparatus having only a conveyor.
FIG. 14: the device shown in fig. 12 has an outer support structure and an inner valve anchored to its inner wall.
FIG. 15: the device shown in fig. 12 is shown with only the external support structure.
FIG. 16: a
FIG. 16 a: another embodiment of the
FIG. 16 b: another embodiment of the
FIG. 16 c: another embodiment of the
FIG. 16 d: another embodiment of the
FIG. 16 e: another embodiment of the
FIG. 16 f: another embodiment of the
FIG. 17: the
FIG. 18: an internal
FIG. 19: a
FIG. 20: the
Detailed Description
Surgery
In this section, the procedure is described by means of an item description relating to an embodiment with a valve, a filter and a transporter element inside an external support structure (see fig. 5). It is contemplated that the procedure is also applicable to other embodiments having different items positioned relative to each other.
The device is collapsed into an external shaft catheter 3 (fig. 1) prior to its introduction into the arterial vessel. The distal portion of the outer shaft catheter is fitted with a
In fig. 3, the device is shown deployed as shown in fig. 2, but the device is equipped with additional features, represented by two
The coronary and periaortic vascular protection systems mentioned above may be applied in virtually any of the embodiments described below.
During function, blood flow in systole passes through the native aortic valve, opening the valve prosthesis and passing through the
Embolic debris is captured and retained within the structure between the
If desired, the device may be left in place for a period of time to allow stabilization of the patient's hemodynamics and then removed. In this case, a special mechanism can be used that forces the prosthetic valve open to verify the restoration of native valve function at the time of treatment, and to repeat the treatment if necessary. The valve opening mechanism mentioned above can be applied in virtually any of the embodiments described below.
At the end of the procedure, the device operating on the native aortic valve is removed from the inner lumen of the transporter 6'. The
The
In particular, mild to severe valvular insufficiency of the native valve may occur after balloon valvuloplasty, suboptimal TAVI implantation, or TAVI misimplantation with subsequent migration. This last condition can be clinically catastrophic, with limited likelihood of patient survival.
In another future situation, the device is absolutely necessary. This is the case with interventional non-extracorporeal surgery to remove the diseased native aortic valve. In this complex procedure during dissection (dissection) of the native valve, anti-embolic protection is mandatory, and more importantly, there is a need to assist aortic valve function while implanting a suture-free valve prosthesis. The device can meet all these requirements.
In certain embodiments, a valve that integrates a embolic filter and a valve prosthesis in a single device may provide two separable components.
In the case of interventional ablation of a diseased aortic valve after its removal, the prosthetic valve can be detached from the
Description of the main elements of the device
Valve prosthesis
The valve allows for temporary replacement of a diseased valve during surgery while allowing the hydrodynamic performance to be compatible with the clinical condition of patients with aortic stenosis.
Support structure
The support structure may be a
Filter
The filter 12 allows retention of embolic debris without significantly altering the hydrodynamic properties of the valve. In some embodiments, the filter and conveyor fabrics are joined as a single element.
Conveyor
The
In some embodiments, the
Inner and outer shaft conduits
The inner shaft conduit 3' permanently supports the
Of course, the present invention is not limited to the embodiments and examples discussed in this document. Thus, the present disclosure should not be limited by any particular elements described below.
More details in terms of materials: for most embodiments, the support structure is described herein as being made of a self-expanding metallic material (e.g., nitinol), but other metallic and non-metallic materials having similar properties may be employed, and non-self-expanding structures, such as polymeric expandable structures, may also be employed; the filter is described as a polymeric woven fabric, but non-woven fabrics (i.e. membranes with calibrated pores) and/or metallic materials with similar properties may also be applied; the valve is described as a polymeric woven fabric coated to ensure leak-free properties, but non-woven fabrics with similar properties may also be applied; the catheter comprises a polymeric tube and further comprises a metal reinforced polymeric tube.
In terms of technology: metallic support structures are described as being obtained from laser-cut tubes or welded plates, from braided (i.e. from multi-strand) and single-wire structures; the coupling between the different elements of the device may be gluing, soldering, welding (i.e. ultrasound), gluing, stitching, and other suitable methods; the valve may be obtained by coating a fabric, but other synthetic or natural materials, such as polymeric films, may also be applied.
With respect to the embodiment: in the description, embodiments are shown which are considered for use in connection with femoral access for restoration of a diseased aortic valve. Also, embodiments with different entry than strands may be applied. For use as a TAVI or suture-free valve prosthesis, specific embodiments may be employed in which the valve portion may be detached by the remainder of the assembly. In this case, the leaflets of the valve may be made of a different material than the polymeric leaflets, such as pericardial tissue or other materials, and the valve structure may also have specific retrieval elements.
Moreover, embodiments for restoring other diseased heart valves may also be applied.
The device may also find application in other fields of technology, such as interventional radiology, as valved or valveless filters for carotid artery protection and repositionable/recapturable venous valves with anti-embolic filters. In this case, the specific embodiment and dimensions of the different elements to be used in the default settings (valves, filters, transporters and associated support structures, catheters) and the intended use (acute, subacute, chronic) will apply.
In terms of dimensions, dimensions relevant for the specific use will be applied, such as the dimensions of the anatomy of the healthy and diseased organ to be treated, the dimensions of the channels for the different transcatheter accesses, the dimensions of the filter against embolisms in the coronary arteries and periaortic arteries.
Fig. 5-11 illustrate one embodiment, hereinafter referred to as a hybrid device, which is a technique for fabricating a laser cut
In this embodiment, the
In fig. 5, the long-axis view of the device in the deployed configuration shows the ring permanently joining the inner shaft catheter 3 'to the outer self-expanding
In fig. 6, a short axis (compartmental) view of the
Fig. 7 shows a
Fig. 7a, 7b, 7c, 7d and 7e show alternative configurations of inflow profiles for ensuring sufficient retrievability and radial stiffness at the same time.
Fig. 8 shows a self-expanding
In fig. 9, both the outer and inner self-expanding
As illustrated in fig. 9a and 9b, the inner elements of the
In fig. 10, the outflow side of the
In the case of the conveyor and the filtering element, the conical shape of the conveyor firstly ensures that the device equipped with an external duct different from the
In fig. 10a, the same elements are seen from the inflow side (compartmental view), showing a two-way normally closed valve at the distal portion of the transporter, which valve ensures no flow during systole to prevent any emboli from passing through the
In terms of a valve, fig. 10 and 10a show the prosthetic valve body 15 from the outflow side and inflow side. A tri-leaflet configuration was chosen, with the leaflets made of a low thickness polymeric fabric, the fibers being elastomer coated and mounted on the exterior of the
Fig. 11 shows the configuration of the
Radiopaque markers are placed to better detect specific locations (e.g., posts and lateral passageways) as well as internal catheter locations (e.g., aortic arch level). The materials, engagement structures, and number of elements are selected based on the prior art and based on the current procedure.
Fig. 12-15 show an alternative embodiment configured as a hybrid embodiment with the conveyor inside the body in order to minimize the overall length, but with both the
Fig. 12 shows a side view of a mesh assembly with the outer
The coupling elements of the superelastic metal
In fig. 13, the
In fig. 14, the
In fig. 15, the sliding coupling between the
Fig. 16-18 show the
Fig. 16, 16a, 17, 18 show elements similar to the hybrid elements (i.e. the coupling between the prosthetic valve 15 and its supporting
In the following figures, some alternative embodiments of the
Fig. 16b, 16c, 16d and 16e show two laser cut and two braided alternative embodiments, respectively, of the
Fig. 16f shows a self-expanding structure that combines the properties of the
In fig. 19 to 20, a specific embodiment of the expansion device is depicted.
The purpose of using an expanded structure is to minimize the number of different materials involved in the manufacture and to allow the burden of folding the device to be reduced. Moreover, due to CO2The radiopaque nature of the filler, which may allow for easy positioning of the device.
Several different embodiments can be applied to the expanded set, starting from the
As far as the opening mechanism of the valve, intended to verify the relevant results of the diseased valve at the end of the recovery procedure, is concerned, different embodiments can be adopted which act directly on the
- 上一篇:一种医用注射器针头装配设备
- 下一篇:假体心脏瓣膜停靠组合件